17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy

被引:5
作者
Karkoulis, Panagiotis K. [1 ]
Stravopodis, Dimitrios J. [2 ]
Voutsinas, Gerassimos E. [1 ]
机构
[1] Natl Ctr Sci Res NCSR Demokritos, Inst Biosci & Applicat, Lab Environm Mutagenesis & Carcinogenesis, Athens 15310, Greece
[2] Univ Athens, Fac Biol, Dept Cell Biol & Biophys, Athens 15784, Greece
关键词
17-DMAG; Apoptosis; Bladder cancer; Hsp90; Metastasis; Signaling; CYCLE ARREST; SIGNAL-TRANSDUCTION; DOWN-REGULATION; HSP90; FUNCTION; INHIBITION; APOPTOSIS; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; CHAPERONE; HEAT-SHOCK-PROTEIN-90; EXPRESSION;
D O I
10.1007/s13277-015-4544-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Heat shock protein 90 (Hsp90) is a molecular chaperone that maintains the structural and functional integrity of various protein clients involved in multiple oncogenic signaling pathways. Hsp90 holds a prominent role in tumorigenesis, as numerous members of its broad clientele are involved in the generation of the hallmark traits of cancer. 17-dimethylamin oethylamino-17-demethoxygeldanamycin (17-DMAG) specifically targets Hsp90 and interferes with its function as a molecular chaperone, impairing its intrinsic ATPase activity and undermining proper folding of multiple protein clients. In this study, we have examined the effects of 17-DMAG on the regulation of Hsp90-dependent tumorigenic signaling pathways directly implicated in cell cycle progression, survival, and motility of human urinary bladder cancer cell lines. We have used MIT-based assays, FACS analysis, Western blotting, semiquantitative PCR (sqPCR), immunofluorescence, and scratch-wound assays in RT4 (p53(wt)). RT112 (p53(wt)), T24 (p53(mt)). and TCCSUP (p53(mt)) human urinary bladder cancer cell lines. We have demonstrated that, upon exposure to 17-DMAG, bladder cancer cells display prominent cell cycle arrest and commitment to apoptotic and autophagic cell death, in a dose-dependent manner. Furthermore, 17-DMAG administration induced pronounced downregulation of multiple Hsp90 protein clients and other downstream oncogenic effectors, therefore causing inhibition of cell proliferation and decline of cell motility due to the molecular "freezing" of critical cytoskeletal components. In toto, we have clearly demonstrated the dose-dependent and cell type-specific effects of 17-DMAG on the hallmark traits of cancer, appointing Hsp90 as a key molecular component in bladder cancer targeted therapy.
引用
收藏
页码:6861 / 6873
页数:13
相关论文
共 34 条
  • [1] Bagatell R, 2004, MOL CANCER THER, V3, P1021
  • [2] Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
    Basso, AD
    Solit, DB
    Munster, PN
    Rosen, N
    [J]. ONCOGENE, 2002, 21 (08) : 1159 - 1166
  • [3] Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death
    Beck, Raphael
    Verrax, Julien
    Gonze, Thomas
    Zappone, Marianne
    Pedrosa, Rozangela Curi
    Taper, Henryk
    Feron, Olivier
    Calderon, Pedro Buc
    [J]. BIOCHEMICAL PHARMACOLOGY, 2009, 77 (03) : 375 - 383
  • [4] New Therapeutic Challenges in Advanced Bladder Cancer
    Bellmunt, Joaquim
    Petrylak, Daniel P.
    [J]. SEMINARS IN ONCOLOGY, 2012, 39 (05) : 598 - 607
  • [5] Cardillo MR, 2000, ANTICANCER RES, V20, P4579
  • [6] Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone
    Clarke, PA
    Hostein, I
    Banerji, U
    Di Stefano, F
    Maloney, A
    Walton, M
    Judson, I
    Workman, P
    [J]. ONCOGENE, 2000, 19 (36) : 4125 - 4133
  • [7] Systemic chemotherapy for advanced bladder cancer: Update and controversies
    Garcia, Jorge A.
    Dreicer, Robert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (35) : 5545 - 5551
  • [8] Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines
    Garcia-Morales, P.
    Carrasco-Garcia, E.
    Ruiz-Rico, P.
    Martinez-Mira, R.
    Menendez-Gutierrez, M. P.
    Ferragut, J. A.
    Saceda, M.
    Martinez-Lacaci, I.
    [J]. ONCOGENE, 2007, 26 (51) : 7185 - 7193
  • [9] Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium
    Goebell, Peter J.
    Knowles, Margaret A.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (04) : 409 - 428
  • [10] Hostein I, 2001, CANCER RES, V61, P4003